News | August 08, 2025
Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Upgrades 2025 full-year CDMO sales and margin outlook
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Subscribe To Our Newsletter & Stay Updated
